Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Inventory (2018 - 2025)

BioNexus Gene Lab's Change in Inventory history spans 8 years, with the latest figure at -$208175.0 for Q3 2025.

  • For Q3 2025, Change in Inventory fell 158.46% year-over-year to -$208175.0; the TTM value through Sep 2025 reached -$25103.0, up 36.58%, while the annual FY2023 figure was -$160387.0, 129.48% down from the prior year.
  • Change in Inventory for Q3 2025 was -$208175.0 at BioNexus Gene Lab, up from -$382481.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $970080.0 in Q4 2022 and bottomed at -$819988.0 in Q2 2021.
  • The 5-year median for Change in Inventory is -$45850.0 (2021), against an average of -$5105.2.
  • The largest YoY upside for Change in Inventory was 23192.69% in 2021 against a maximum downside of 2677.36% in 2021.
  • A 5-year view of Change in Inventory shows it stood at -$34236.0 in 2021, then skyrocketed by 2933.51% to $970080.0 in 2022, then crashed by 129.99% to -$290889.0 in 2023, then surged by 222.41% to $356073.0 in 2024, then plummeted by 158.46% to -$208175.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Change in Inventory are -$208175.0 (Q3 2025), -$382481.0 (Q2 2025), and $209480.0 (Q1 2025).